→ Actelion spinout Idorsia says it scored positive data from two Phase II studies of a new sleep drug called ACT-541468. Investigators say that they designed this drug with two key features in mind: keep people asleep through the night with few lingering side effects after they wake up. They tested the drug in 418 patients, reporting on top-line results. And now the company plans to move into Phase III. “I am delighted to see that the positive readouts from this comprehensive Phase 2 program are consistent with our preclinical predictive models, for both adult and elderly patients with insomnia,” said CSO Martine Clozel.
→ France’s Servier has taken an option on an osteoarthritis drug discovered at Galapagos. Servier gets global rights outside the US in the deal, paying a €6 million license fee and committing to €290 million in milestones. The mechanism of action of GLPG1972/S201086 targets a cartilage degrading enzyme called ADAMTS-5.
→ Prominent UK investor Neil Woodford took up the case in favor of AstraZeneca this week. After the MYSTIC fail damaged the pharma giant’s shares, Woodford — like CEO Pascal Soriot — insisted there are plenty of reasons to believe that AstraZeneca can succeed.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,100+ biopharma pros who read Endpoints News by email every day.Free Subscription